Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2025 MDS Highlights
03 February 2026 | Virtual Webinar
Post-ASH 2025 MDS Highlights
Featuring presentations & discussions on selected MDS abstracts from the 67th ASH Annual Meeting and Exposition
Tuesday 3 February | 08:00 – 10:00 CST/ 14:00 – 16:00 GMT/ 15:00 – 17:00 CET
Chair: Amer Zeidan | Moderators: Hetty Carraway and Ioannis Kotsianidis
The Post-ASH 2025 MDS Highlights is supported by BMS (Platinum Sponsor) and Faron Pharmaceuticals (Silver Sponsor). Supporters have no influence over the production of content.
Explore the presentations and discussions below:
Session 1: Recent developments in higher-risk MDS
Subgroup analyses from the randomized, Phase III VERONA study of venetoclax with azacitidine versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk MDS
Gail Roboz Weill Medical College of Cornell University, New York City, NY, United States
Outcomes of patients with HR-MDS treated with hypomethylating agents + venetoclax – a large analysis from the international consortium for MDS (icMDS) validate database
Jan Bewersdorf Yale Cancer Center, New Haven, CT, United States
Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the BEXMAB Phase 1/2 study
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes
Julie Braish University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel Discussion
Session 2: Latest treatment approaches in lower-risk MDS
Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial
Kelly Bolton Washington University in St. Louis, St. Louis, MO, United States
A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk myelodysplastic syndromes
Ian Bouligny The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge trial
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial
Valeria Santini University of Florence, Florence, Italy
Elritercept shows durable responses in lower-risk myelodysplastic neoplasms (LR-MDS) with transfusion dependence: Updated results from an ongoing Phase 2 trial
Lynette Chee The Royal Melbourne Hospital & Peter MacCallum Cancer Centre, Melbourne, Australia
Safety and efficacy results from A phase 1b study of R289, a dual irak 1/4 inhibitor, in patients with Relapsed/Refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS)
Hetty Carraway Cleveland Clinic, Cleveland, OH, United States
Panel Discussion
Session 3: Additional novel therapies for myeloid malignancies
MC210807: Phase 1 clinical trial assessing the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in relapsed/refractory myeloproliferative chronic myelomonocytic leukemia (CMML)
Mrinal Patnaik Mayo Clinic, Rochester, MN, United States
Presentation coming soon
A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
Andrew Brunner Massachusetts General Hospital, Boston, MA, United States
Presentation coming soon
ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial
Daniel Wiseman The Christie NHS Foundation Trust, Manchester, United Kingdom
Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘Austrian myeloid registry’ (NCT04438889) of the AGMT study group
Lisa Pleyer Paracelsus Medical University, Salzberg, Austria
Interim results of the CMML intercept study: A prospective observational study to evaluate the role of acute inflammation in CMML disease progression
Zhuoer Xie Moffitt Cancer Center, Rochester, MN, United States
Panel Discussion
